NM_000093.5(COL5A1):c.1561A>G (p.Met521Val) AND Ehlers-Danlos syndrome, classic type, 1
- Germline classification:
- Conflicting interpretations of pathogenicity (2 submissions)
- Last evaluated:
- Jul 17, 2023
- Review status:
- Somatic classification
of clinical impact: - None
- Review status:
- Somatic classification
of oncogenicity: - None
- Review status:
- Record status:
- current
- Accession:
- RCV002228840.13
Allele description [Variation Report for NM_000093.5(COL5A1):c.1561A>G (p.Met521Val)]
NM_000093.5(COL5A1):c.1561A>G (p.Met521Val)
Condition(s)
- Name:
- Ehlers-Danlos syndrome, classic type, 1 (EDSCL1)
- Synonyms:
- EHLERS-DANLOS SYNDROME, GRAVIS TYPE; EHLERS-DANLOS SYNDROME, SEVERE CLASSIC TYPE; Ehlers-Danlos syndrome, type 1; See all synonyms [MedGen]
- Identifiers:
- MONDO: MONDO:0019567; MedGen: C0268335; OMIM: 130000
-
PREDICTED: Oryctolagus cuniculus polyamine oxidase (PAOX), transcript variant X2...
PREDICTED: Oryctolagus cuniculus polyamine oxidase (PAOX), transcript variant X2, mRNAgi|2327351320|ref|XM_002718768.4|Nucleotide
-
PREDICTED: Rattus norvegicus nuclear factor of activated T-cells 2 (Nfatc2), tra...
PREDICTED: Rattus norvegicus nuclear factor of activated T-cells 2 (Nfatc2), transcript variant X1, mRNAgi|2678929884|ref|XM_017591799.3|Nucleotide
-
PREDICTED: Rattus norvegicus nuclear factor of activated T-cells 2 (Nfatc2), tra...
PREDICTED: Rattus norvegicus nuclear factor of activated T-cells 2 (Nfatc2), transcript variant X5, mRNAgi|2678929888|ref|XM_006235653.3|Nucleotide
-
nuclear factor of activated T-cells, cytoplasmic 2 isoform X3 [Rattus norvegicus...
nuclear factor of activated T-cells, cytoplasmic 2 isoform X3 [Rattus norvegicus]gi|1958762251|ref|XP_038961071.1|Protein
-
Mus musculus trophoblast glycoprotein (Tpbg), transcript variant 1, mRNA
Mus musculus trophoblast glycoprotein (Tpbg), transcript variant 1, mRNAgi|2772229858|ref|NM_011627.5|Nucleotide
Your browsing activity is empty.
Activity recording is turned off.
See more...Assertion and evidence details
Last Updated: Nov 3, 2024